• Policy
• 9th meeting held for external reference pricing reevals
• by Lee, Tak-Sun Jun 13, 2024 05:48am

• Policy
• Price ceiling for 'atosiban' set to rise under agreements
• by Lee, Tak-Sun Jun 12, 2024 05:45am

• Policy
• Approval for PH-ILD inhalation drug 'Tyvaso' expected soon
• by Lee, Hye-Kyung Jun 11, 2024 05:48am

• Policy
• Handok paces its efforts to reimburse Pivlaz in KOR
• by Lee, Tak-Sun Jun 11, 2024 05:47am

• Policy
• Roche applies for Ocrevus' reimbursement in KOR
• by Lee, Tak-Sun Jun 10, 2024 05:41am

• Policy
• Latuda·Dupixent enter negotiations with the NHIS
• by Lee, Tak-Sun Jun 7, 2024 05:50am

• Policy
• Gov’t will maintain criteria for KIPC recertifications
• by Lee, Jeong-Hwan Jun 5, 2024 05:47am

• Policy
• Lorviqua fails to receive reimb as first-line therapy
• by Lee, Tak-Sun Jun 4, 2024 05:47am

• Policy
• Takeda’s Zejula Tab receives marketing authorization in KOR
• by Lee, Hye-Kyung Jun 3, 2024 05:49am

• Policy
• Qarziba’s reimb standard has been set before approval
• by Lee, Tak-Sun May 31, 2024 05:51am